Cointime

Cullinan Oncology

company

About

Cullinan Oncology is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

  • 11 - 50

Highlights

Total Funding Amount
$150M
Funding Rounds
1
Investors
2

Details

Last Funding Type
Series A
Last Funding Money Raised
$150M
Industries
Biopharma,Biotechnology,Medical Device
Founded date
Jan 1, 2017
Number Of Employee
11 - 50
Operating Status
Active

Cullinan Oncology is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$150M
Cullinan Oncology has raised a total of $150M in funding over 2 rounds. Their latest funding was raised on Oct 3, 2017 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 3, 2017 Series A $150M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Cullinan Oncology is funded by 2 investors. UBS Oncology Impact Fund and Park Vale Capital are the most recent investors.
Investor Name Lead Investor Funding Round
UBS Oncology Impact Fund — Series A
Park Vale Capital — Series A
Cointime
Содержание
компания